Holen Sie sich die Stockscreener-App
12.21
2.35%
0.28
Handel nachbörslich:
12.21
Schlusskurs vom Vortag:
$11.93
Offen:
$11.93
24-Stunden-Volumen:
533.00K
Relative Volume:
0.93
Marktkapitalisierung:
$514.21M
Einnahmen:
$82.71M
Nettoeinkommen (Verlust:
$-102.24M
KGV:
-2.609
EPS:
-4.68
Netto-Cashflow:
$-76.57M
1W Leistung:
-0.33%
1M Leistung:
-3.86%
6M Leistung:
-14.62%
1J Leistung:
+5.53%
1-Tages-Spanne:
$11.65
$12.30
1-Wochen-Bereich:
$11.65
$13.33
52-Wochen-Spanne:
$10.60
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference - StockTitan
(URGN) Investment Analysis - Stock Traders Daily
Rice Hall James & Associates LLC Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen Pharma (URGN) to Release Quarterly Earnings on Wednesday - MarketBeat
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - BioSpace
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - StockTitan
(URGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
UroGen started at buy by EF Hutton, RTGel technology cited - MSN
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years - Yahoo Finance
FDA accepts UroGen's NDA for bladder cancer treatment - Investing.com India
When Would Be The Best Time To Buy UroGen Pharma Ltd (NASDAQ: URGN) Stock? - Stocks Register
URGN’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
UroGen Pharma maintains Outperform stock rating on new drug application - Investing.com
UroGen Pharma Ltd (URGN) looking to reclaim success with recent performance - SETE News
UroGen Pharma maintains Outperform stock rating on new drug application By Investing.com - Investing.com UK
UroGen Pharma (NASDAQ:URGN) Receives "Outperform" Rating from Oppenheimer - MarketBeat
Wesbanco Bank Inc. Buys Shares of 74,400 UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment - Pharmaceutical Technology
UroGen Pharma Says FDA Accepts NDA for UGN-102 - Marketscreener.com
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - The Bakersfield Californian
UroGen Pharma Ltd (URGN) is a good investment, but the stock may be undervalued - US Post News
UroGen Pharma's (URGN) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
UroGen Pharma (NASDAQ:URGN) Lifted to Strong-Buy at EF Hutton Acquisition Co. I - MarketBeat
EF Hutton initiates UroGen Pharma shares with Buy rating By Investing.com - Investing.com South Africa
EF Hutton Initiates Coverage of UroGen Pharma (URGN) with Buy Recommendation - MSN
UroGen Pharma Ltd [URGN] Chief Medical Officer makes an insider sale of 859 shares worth 11,236. - Knox Daily
Healthy Upside Potential: UroGen Pharma Ltd (URGN) - SETE News
UroGen Pharma announces executive changes By Investing.com - Investing.com South Africa
UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
UroGen Pharma Announces Departure of CFO and Appointment of New CFO - MarketBeat
UroGen Appoints Chris Degnan as Chief Financial Officer - citybiz
UroGen Pharma announces executive changes - Investing.com
Urogen Pharma falls on CFO appointment - XM
UroGen Pharma Announces CFO Transition and Compensation Details - TipRanks
UroGen Pharma appoints Chris Degnan as CFO - Investing.com
Marshall Wace LLP Buys Shares of 42,841 UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
News: UroGen Pharma Ltd’s Chief Medical Officer Schoenberg Mark reduceds 859 shares - Knox Daily
What technical indicators reveal about URGN stock - US Post News
Market Update: UroGen Pharma Ltd (URGN) Sees Negative Movement, Closing at 12.42 - The Dwinnex
Millennium Management LLC Purchases 1,119,019 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen Pharma (STU:UR8) 9-Day RSI : 49.01 (As of Nov. 03, 2024) - GuruFocus.com
UroGen begins subject dosing in Phase III bladder cancer drug trial - Clinical Trials Arena
UroGen Pharma retains Buy rating from H.C. Wainwright By Investing.com - Investing.com Australia
UroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at HC Wainwright - MarketBeat
URGN (UroGen Pharma Ltd) may reap gains as insiders became active recently - Knox Daily
Stock Surge: UroGen Pharma Ltd (URGN) Closes at 12.48, Marking a -1.73 Increase/Decrease - The Dwinnex
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Business Wire
Is the UroGen Pharma Ltd (NASDAQ:URGN) stock an investment opportunity? - US Post News
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Acquired by Point72 Asset Management L.P. - MarketBeat
UroGen Pharma secures $25M loan, eyes FDA drug approval By Investing.com - Investing.com Australia
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):